News Search Results
Sep 26, 2025, 10:30 ET Smart Sleep Tracker Market is expected to generate a revenue of USD 68.31 Billion by 2032, Globally, at 12.4% CAGR: Verified Market Research®
health and wellness is driving strong demand for smart sleep trackers. Increasing cases of sleep disorders, stress-related insomnia, and lifestyle diseases are prompting individuals to monitor their sleep patterns.Smart sleep trackers provide actionable insights for better
More news about: Verified Market Research
Sep 25, 2025, 10:44 ET Mental Health Apps Market to Hit US$15.69 Bn by 2033 Amid Rising Wellness Awareness, Says DataM Intelligence Report
and communities acknowledge mental well-being, the demand for accessible digital tools to manage conditions like anxiety, depression, stress, and insomnia continues to rise. This awareness fosters a greater need for effective, user-friendly mental health platforms. Mental health apps serve as
More news about: DataM Intelligence 4 Market Research LLP
Sep 25, 2025, 08:00 ET Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
approval for HETLIOZ® in the treatment of insomnia and Jet Lag Disorder and is continuing to develop HETLIOZ® for the treatment of several other sleep disorders including Delayed Sleep Phase Disorder (DSPD) and pediatric insomnia. References: Synnott NC,
More news about: Vanda Pharmaceuticals Inc.
Sep 24, 2025, 13:18 ET Fusion CBD Products' Sleep and Recovery Softgels Could Help You Conquer Insomnia
Mayo Clinic has outlined ways to combat insomnia and ensure you're getting sufficient sleep. These include: sticking to a sleep schedule to reinforce your body's sleep-wake cycle; avoiding
More news about: Fusion CBD Products
Sep 23, 2025, 09:03 ET Philadelphia Sleep Specialist Dr. Funke Afolabi-Brown Announces Grand Opening Ceremony of The Restful Sleep Place
treatment for sleep disorders including insomnia,
More news about: The Restful Sleep Place
Sep 22, 2025, 08:30 ET Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
3 (6.4) Insomnia 2 (2.2)
More news about: Neurocrine Biosciences, Inc.
Sep 22, 2025, 07:45 ET Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
patients at recommended doses, one patient reported insomnia following abrupt discontinuation of XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory
More news about: Jazz Pharmaceuticals plc
Sep 19, 2025, 11:01 ET Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR - DataM Intelligence
The global sleep aids market is witnessing robust growth, driven by the rising prevalence of sleep disorders such as insomnia, sleep apnea, and restless legs syndrome, along with increasing awareness about the health risks of untreated sleep disturbances. Advances in medications,
More news about: DataM Intelligence 4 Market Research LLP
Sep 18, 2025, 06:45 ET Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection)
disorders. Monitor for signs of perforation and bleeding Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated Patients with comorbid
More news about: Mallinckrodt plc
Sep 16, 2025, 18:01 ET EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
further contributed to risk. Adults with suicidal thoughts reported higher levels of stigmatisation and more prevalent sleep disorders, with mixed insomnia – difficulty falling and staying asleep – notably linked to suicidal ideation (OR=1.78). Dr Delphine Kerob, one of the lead researchers, commented,
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 16, 2025, 18:01 ET EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
further contributed to risk. Adults with suicidal thoughts reported higher levels of stigmatisation and more prevalent sleep disorders, with mixed insomnia – difficulty falling and staying asleep – notably linked to suicidal ideation (OR=1.78). Dr Delphine Kerob, one of the lead researchers, commented,
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 16, 2025, 10:14 ET 5 Surprising Tricks for When You Can't Sleep, a Free Guide to Support Better Rest From Pacific Mind Health
"Sometimes just having a new approach gives you the confidence and calm you need to reset and rest." The free guide arrives at a time when insomnia and disrupted sleep are on the rise. About 50 to 70 million Americans chronically suffer from sleep and wakefulness disorders, according to the Institute
More news about: Pacific Mind Health
Sep 15, 2025, 09:00 ET New Oova Perimenopause Tracker Tells Women Their Stage of Menopause and More
over 30,000 menstrual cycles, Oova can present to users predictable connections between hormone fluctuations and symptoms including hot flashes, insomnia, and mood changes.
More news about: Oova
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
is often accompanied by sleep disturbances such as insomnia or hypersomnia, with approximately 60 percent of MDD patients experiencing insomnia symptoms despite being on standard-of-care oral antidepressants.12 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality
More news about: Johnson & Johnson
Sep 11, 2025, 13:00 ET Insomnia Cookies is Hosting the Biggest PJ Party of the Year with Its Seventh Annual PJ Party Event
including glowsticks, Insomnia Cookies swag and more. Insomnia is partnering with Red Bull at five participating college campus bakeries, providing energy for the night with Red Bull™ Energy Drink Infusions. Founded on a university campus, Insomnia Cookies hosts its
More news about: Insomnia Cookies
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin minitablet indicated for the treatment of insomnia in children and adolescents aged 2 to <18 years with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where
More news about: Neurim Pharmaceuticals
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin minitablet indicated for the treatment of insomnia in children and adolescents aged 2 to <18 years with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where
More news about: Neurim Pharmaceuticals
![Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])](https://mma.prnewswire.com/media/633165/PTx_updated_logo.jpg?w=300){kind=logo}
Sep 09, 2025, 13:42 ET Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])
hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increased creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albuminIn patients with AML–fever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory
More news about: Partner Therapeutics, Inc.
Sep 09, 2025, 11:09 ET PCORI awards new patient-centered CER to support informed health care decisions
challenges Among the newly awarded patient-centered CER studies, two focus on sleep health. One will compare treatment approaches for insomnia and another for sleep apnea — both common conditions affecting millions of adults. Another study will compare approaches including nondrug
More news about: Patient-Centered Outcomes Research Institute
Sep 08, 2025, 03:15 ET Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
group. Most TEAEs were mild to moderate in severity. The most common TEAEs7 were pollakiuria, insomnia, salivary hypersecretion, urinary urgency and blurred vision. Events of insomnia largely occurred and resolved within the first week of dosing. Events of blurred vision were mostly mild and
More news about: Alkermes plc
Sep 08, 2025, 00:01 ET Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
believed to help maintain a more stable state of wakefulness. From the perspective of inhibiting orexinergic neuron activity, Eisai has developed the insomnia treatment DAYVIGO ® (generic name: lemborexant) an orexin receptor antagonist that is available in more than 25 countries worldwide. Furthermore,
More news about: Eisai Inc.
Sep 05, 2025, 08:00 ET Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension
a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising
More news about: Idorsia Pharmaceuticals Ltd.
Sep 04, 2025, 10:05 ET Former U.S. Federal CIO Joins Nox Health Board, Bringing Proven Government Leadership to Drive Healthcare Innovation and Cost Savings
"Her perspective will help shape the future of our work as we grow our capabilities in diagnostic solutions, prescription therapeutics for chronic insomnia, and comprehensive sleep care management." "I am honored to join the Nox Board of Directors and support its mission," said Clare
More news about: Nox Health
Sep 03, 2025, 19:30 ET Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
people diagnosed with narcolepsy type 1 (NT1) and the Phase IV clinical study (SELENADE Study) investigating the effect of lemborexant in people whose insomnia was comorbid with depressive episodes of major depressive disorder and bipolar disorder (Poster 3-133). The company will also host a symposium introducing
More news about: Eisai Inc.
Sep 03, 2025, 10:00 ET Is Indoor Mold Affecting Your Mental Health?
ailment during her 40+ years in the healthcare industry. As the skin breakouts continued to spread to her head and legs, she then started experiencing insomnia, fatigue, anxiety, depression, dizziness and headaches. When fevers, muscle twitching, and body pain began, Cheske knew that the cause of her physical
More news about: Mold Hunt